U.S. Markets open in 7 hrs 20 mins

Aeterna Zentaris Inc. (AEZS)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.9801-0.02 (-1.88%)
At close: 4:00PM EDT
People also watch
KERXCYCCCTICGALESNSS
  • Buy DXTR now this Friday $1.3
    Imagetvsaiditnotme
  • IGXT (MC $50 M) NDA filing for MEGA thin-flim Cialis (better than Viagra) this month =10++ BAGGER Potential ! PLEASE read this guys and then join us to make big money .A LIFETIME OPPORTUNITY HERE GUYS !!!

    2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $50 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .Load up guys before she the MEGA news hit the wire and thank me later .GL

    Intelgenx (IGXT)

    MarketCap $50 Million
    Cash ~$12 Million (including convertible debt) =cash untill 2021+
    Price: 0.80

    NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July
    NDA resubmission for Rizaport (migraine) in early Q3
    Partnership for Tadalafil in 2H 2017

    http://www.biotuesdays.com/features/2017/5/11/intelgenx-has-multi-faceted-bd-approach-for-its-oral-films

    IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.

    Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.

    IntelGenx has multi-faceted BD approach for its oral films
    With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing
    www.biotuesdays.com
  • Wow, now that was quick ...back under 1$ already ...somebody wake up Dodd, time for some more dilution methinks:-)

    A world beating Biotech with the greatest ("Rip off") CEO, ever to grace the face of this planet
  • Monster MicroCaps SPECIAL ALERT to AEZS shareholders – NWBO $.19 and climbing, just announced $11 million financing with convertible debt payable in 3 years at $0.25, $.50 and $1.00. NWBO expected to release final Phase III Trial results any day from now until mid-July. If results are comparable to preliminary data, shares likely to explode to yield enormous percentage gains. Announcement could be huge because DCVax-L and DCVax Direct are also proven effective against 13 common cancers and has only mild fever as potential side effect. This breakthrough immunotherapy might replace the $100 Billion chemotherapy market.
    https://finance.yahoo.com/news/nwbio-closes-3-convertible-debt-154100683.html

    NWBio Closes 3-Year Convertible Debt Exchange and Financing, and Completes Payoff of Last $5 Million of 2014 Bonds
    This completes the Company's payoff of $11 million in principal amount of bonds, plus associated interest and forbearance fees, over the period from March through June of this year in accordance with an installment payment agreement with the bondhold
    finance.yahoo.com
  • Here we GO, ladies - "implied volatility".
    Tighten your bra straps ......
    Imageetudiant-en-ph2
  • I am all in Dextera Surgical Inc

    (NASDAQ:DXTR) let see this holidays %200 up, buy out
  • A man may die, nations may rise and fall, but an idea lives on.http://dataunion.tistory.com/10812

    AEterna Zentaris Inc. NASDAQ : AEZS Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is -0.9 In other words, the correlation coefficient of the other stoc
    dataunion.tistory.com
  • If we are to go off the RSI then you could argue that a pull back next day or so could occur on AEZS before rallying up. have you guys heard of AWEsome_STOCK.S. i started receiving their allerts and so far i am happy.
  • Here we GO, ladies - "implied volatility".
    Tighten your bra straps ......
  • Investors in Aeterna Zentaris Inc. (AEZS - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the August 18th, 2017 $7.50 Call had some of the highest implied volatility of all equity options today.
    Imagejdm-negan-mcnaughty
  • LOAD UP OR LOAD OUT ?
    Imagejenesuispasunefilleparfaite
  • LOAD UP, people!
    Imagesimplysamnicole
  • Imagelittlepawz
  • if you lost money in this POS like I did, buy DVAX. it is up after hours because of the combination drug with Keytura.
  • Guys DCTH will see $6 anytime.... FDA Approval.

    The agency’s SPA nod has gone ahead to say that the trial design in an adequate way addresses the set goals for evaluating Melphalan/HDS for handling the wide range of patients with intrahepatic cholangiocarcinoma (ICC).According to some close sources, about 295 patients are expected to be enrolled in the global trial at 40 different sites in Europe and in the U.S.

    There are hopes that by the fall of 2017 the trial will have kick started and as a matter of fact it will bear the overall survival (OS) as its primary endpoint.

    Measures of progression-free survival (PFS), safety as well as overall response rate (ORR) are expected to constitute the wide array of the exploratory and secondary endpoints. It is also important to point to the fact that it isn’t easy to reach the point the provider has reached at the moment since on the way it is usually marred by numerous challenges.

    In fact there comes a moment when efforts appear like the drawing of lines in the sand. However, the top notch provider has remained dedicated to coming up with top most solutions and for sure the future looks quite promising.
    Imageasvpxosas
  • Tighten your bra straps, girls.
    Prepare for blastoff.
    Imagemodelcaradelevingnex
  • Imagerelatablexp
  • Imageacnlvevo
  • SMOKING pre-market !!
    COVER your short !!!
    Imagemasochistphil
  • possible big news: Takeover
    Its cash($17 m) is more than SP ($16 m), and has a drug near FDA approval. Any drug company would love to have it if they are not fools.